The bottleneck in AZT activation
- 1 August 1997
- journal article
- Published by Springer Nature in Nature Medicine
- Vol. 3 (8) , 922-924
- https://doi.org/10.1038/nm0897-922
Abstract
Nucleoside-based inhibitors of reverse transcriptase were the first drugs to be used in the chemotherapy of AIDS. After entering the cell, these substances are activated to their triphosphate form by cellular kinases, after which they are potent chain terminators for the growing viral DNA (ref. 1). The two main factors limiting their efficacy are probably interrelated. These are the insufficient degree of reduction of viral load at the commencement of treatment and the emergence of resistant variants of the virus. The reason for the relatively poor suppression of viral replication appears to be inefficient metabolic activation. Thus, for the most extensively used drug, 3′-azido-3′-de-oxythymidine (AZT), whereas phosphorylation to the monophosphate is facile, the product is a very poor substrate for the next kinase in the cascade, thymidylate kinase2,3. Because of this, although high concentrations of the monophosphate can be reached in the cell, the achievable concentration of the active triphosphate is several orders of magnitude lower. Determination of the structure of thymidylate kinase as a complex with AZT monophosphate (AZTMP) together with studies on the kinetics of its phosphorylation have now led to a detailed understanding of the reasons for and consequences of the poor substrate properties.Keywords
This publication has 13 references indexed in Scilit:
- 3′-Azidothymidine (Zidovudine) Inhibits Glycosylation and Dramatically Alters Glycosphingolipid Synthesis in Whole Cells at Clinically Relevant ConcentrationsPublished by Elsevier ,1995
- Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas antihuman immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine-5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cellsBiochemical Pharmacology, 1995
- Metabolism of 3′-azido-3′-deoxythymidine (AZT) in human placentae trophoblasts and Hofbauer cellsBiochemical Pharmacology, 1994
- Inhibition of mammalian dna polymerase-associated 3′ to 5′ exonuclease activity by 5′-monophosphates of 3′-azido-3′-deoxythymidine and 3′-amino-3′-deoxythymidineBiochemical Pharmacology, 1993
- 3'-azido-3'-deoxythymidine (AZT) monophosphate: an inhibitor of exonucleolytic repair of AZT-terminated DNAAntimicrobial Agents and Chemotherapy, 1993
- Factors contributing to the inhibition of HIV reverse transcriptase by chain‐terminating nucleotides in vitro and in vivoFEBS Letters, 1991
- Interaction of fluorescently labeled dideoxynucleotides with HIV-1 reverse transcriptaseBiochemistry, 1991
- The P-loop — a common motif in ATP- and GTP-binding proteinsTrends in Biochemical Sciences, 1990
- Effects of 3′-azido-3′-deoxythymidine on the deoxynucleotide triphosphate pools of cultured human cellsBiochemical and Biophysical Research Communications, 1988
- Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.Proceedings of the National Academy of Sciences, 1986